IMMUNE MONITORING & FLOW CYTOMETRY SHARED RESOURCE (IM&FCSR) The Immune Monitoring and Flow Cytometry Shared Resource (IM&FCSR) provides investigators with services and research expertise, supporting a wide range of laboratory and clinical studies in cancer immunology and immunotherapy, transplant biology, infectious disease, and vaccine development. The IM&FCSR produces custom-made tetramer complexes of specific peptide and major histocompatibility complex molecules as unique reagents for assessing antigen-specific T cells and isolating these T cells for therapy trials. Our flow cytometry service offers a wide range of instrumentation, from single-laser benchtop analyzers to complex multi-laser cell sorters. We provide protocol-specific, flow cytometric immune monitoring to support immunotherapy trials. We quantify cytokine proteins, as a measure of immune and other cellular function, at technology platforms of high multiplicity, single cell, and/or ultrasensitivity. We perform specific cellular and molecular assays of native and genetically engineered T cells for laboratory research studies and for monitoring clinical samples. Technical assistance is available for data evaluation and interpretation, as is assistance in optimal experimental design. The different dataset we can provide enable the characterization of immune cell?s phenotypes and functionality, determining immune responses and tracking, and monitoring of immune cell products during immunotherapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853652
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Kuzma, Jessica N; Cromer, Gail; Hagman, Derek K et al. (2018) Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans. Eur J Clin Nutr :
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Puré, Ellen; Hingorani, Sunil R (2018) Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends Cancer 4:273-277
Yu, Hsiang; Cheng, Yu-Jen; Wang, Ching-Yun (2018) Methods for multivariate recurrent event data with measurement error and informative censoring. Biometrics 74:966-976
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005
Winters, Brian R; Vakar-Lopez, Funda; Brown, Lisha et al. (2018) Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol Oncol 36:342.e7-342.e14
Molina, Yamile; Briant, Katherine J; Sanchez, Janeth I et al. (2018) Knowledge and social engagement change in intention to be screened for colorectal cancer. Ethn Health 23:461-479
Briant, Katherine J; Sanchez, Janeth I; Ibarra, Genoveva et al. (2018) Using a Culturally Tailored Intervention to Increase Colorectal Cancer Knowledge and Screening among Hispanics in a Rural Community. Cancer Epidemiol Biomarkers Prev 27:1283-1288
Xu, Chang; Nikolova, Olga; Basom, Ryan S et al. (2018) Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer. Clin Cancer Res 24:2828-2843

Showing the most recent 10 out of 1267 publications